ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00112346

Public ClinicalTrials.gov record NCT00112346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Multicenter Phase II Study of Gemcitabine/Platinum/Cetuximab Versus Gemcitabine/Platinum as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT00112346
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

  • Cetuximab + platinum + gemcitabine Drug
  • Platinum + Gemcitabine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2004
Primary completion
Nov 30, 2006
Completion
Nov 30, 2006
Last update posted
Oct 27, 2015

2005 – 2006

United States locations

U.S. sites
31
U.S. states
20
U.S. cities
31
Facility City State ZIP Site status
Local Institution Mobile Alabama
Local Institution Anchorage Alaska
Local Institution Bakersfield California
Local Institution Corona California
Local Institution Oxnard California
Local Institution San Diego California
Local Institution Whittier California
Local Institution Lakewood Colorado
Local Institution Boynton Beach Florida
Local Institution Brooksville Florida
Local Institution Inverness Florida
Local Institution Pembroke Pines Florida
Local Institution Austell Georgia
Local Institution Honolulu Hawaii
Local Institution Skokie Illinois
Local Institution Muncie Indiana
Local Institution Annapolis Maryland
Local Institution Frederick Maryland
Local Institution Rockville Maryland
Local Institution Plymouth Massachusetts
Local Institution Farmington New Mexico
Local Institution Armonk New York
Local Institution Stony Brook New York
Local Institution Gastonia North Carolina
Local Institution Wilmington North Carolina
Local Institution Bismarck North Dakota
Local Institution Cincinnati Ohio
Local Institution Portland Oregon
Local Institution Charleston South Carolina
Local Institution Dallas Texas
Local Institution Vancouver Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00112346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 27, 2015 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00112346 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →